Literature DB >> 31384364

Outcomes of Hemorrhagic Stroke Patients with Atrial Fibrillation or Flutter.

Sadaf Farasat1, Asa Tsoi2, Kyulim Lee2, Craig I Coleman2, Elaine Nguyen3.   

Abstract

INTRODUCTION: Hemorrhagic stroke is a life-threatening complication, and may be particularly prevalent in patients with atrial fibrillation/flutter (AF/AFL) due to their need for anticoagulation. We sought to estimate in-hospital mortality, length of stay (LOS) and in-patient treatment cost of patients with AF/AFL admitted with hemorrhagic stroke.
METHODS: We used the 2008-2011 National Inpatient Sample to identify adult AF/AFL patients with a principle discharge diagnosis of subarachnoid or intracerebral hemorrhage. Endpoints of interest included in-hospital mortality, LOS, and hospital treatment costs (2015 US$).
RESULTS: In-hospital mortality for subarachnoid and intracerebral hemorrhage was 31.3% and 31.8%, respectively. Patients had a median LOS of 5 days and 25% of patients accrued costs in excess of $24,107/stay.
CONCLUSIONS: Admissions for hemorrhagic stroke among patients with AF/AFL were associated with substantial in-hospital mortality and treatment costs.

Entities:  

Keywords:  Atrial fibrillation; Cost ; Hemorrhagic stroke; Length of stay; Mortality

Year:  2019        PMID: 31384364      PMCID: PMC6652795          DOI: 10.4022/jafib.2144

Source DB:  PubMed          Journal:  J Atr Fibrillation        ISSN: 1941-6911


  8 in total

1.  Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association.

Authors:  Dariush Mozaffarian; Emelia J Benjamin; Alan S Go; Donna K Arnett; Michael J Blaha; Mary Cushman; Sandeep R Das; Sarah de Ferranti; Jean-Pierre Després; Heather J Fullerton; Virginia J Howard; Mark D Huffman; Carmen R Isasi; Monik C Jiménez; Suzanne E Judd; Brett M Kissela; Judith H Lichtman; Lynda D Lisabeth; Simin Liu; Rachel H Mackey; David J Magid; Darren K McGuire; Emile R Mohler; Claudia S Moy; Paul Muntner; Michael E Mussolino; Khurram Nasir; Robert W Neumar; Graham Nichol; Latha Palaniappan; Dilip K Pandey; Mathew J Reeves; Carlos J Rodriguez; Wayne Rosamond; Paul D Sorlie; Joel Stein; Amytis Towfighi; Tanya N Turan; Salim S Virani; Daniel Woo; Robert W Yeh; Melanie B Turner
Journal:  Circulation       Date:  2015-12-16       Impact factor: 29.690

2.  A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study.

Authors:  Margaret C Fang; Alan S Go; Yuchiao Chang; Leila H Borowsky; Niela K Pomernacki; Natalia Udaltsova; Daniel E Singer
Journal:  J Am Coll Cardiol       Date:  2011-07-19       Impact factor: 24.094

Review 3.  Common flaws exist in published cost-effectiveness models of pharmacologic stroke prevention in atrial fibrillation.

Authors:  Brendan L Limone; William L Baker; Elizabeth S Mearns; C Michael White; Jeffrey Kluger; Craig I Coleman
Journal:  J Clin Epidemiol       Date:  2014-07-10       Impact factor: 6.437

Review 4.  2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Joseph S Alpert; Hugh Calkins; Joaquin E Cigarroa; Joseph C Cleveland; Jamie B Conti; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Katherine T Murray; Ralph L Sacco; William G Stevenson; Patrick J Tchou; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2014-03-28       Impact factor: 24.094

5.  Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation.

Authors:  B F Gage; A D Waterman; W Shannon; M Boechler; M W Rich; M J Radford
Journal:  JAMA       Date:  2001-06-13       Impact factor: 56.272

6.  Accuracy of ICD-9-CM codes for identifying cardiovascular and stroke risk factors.

Authors:  Elena Birman-Deych; Amy D Waterman; Yan Yan; David S Nilasena; Martha J Radford; Brian F Gage
Journal:  Med Care       Date:  2005-05       Impact factor: 2.983

7.  Intracranial hemorrhage mortality in atrial fibrillation patients treated with dabigatran or warfarin.

Authors:  Alvaro Alonso; Lindsay G S Bengtson; Richard F MacLehose; Pamela L Lutsey; Lin Y Chen; Kamakshi Lakshminarayan
Journal:  Stroke       Date:  2014-07-03       Impact factor: 7.914

8.  Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation.

Authors:  A John Camm; Gabriele Accetta; Giuseppe Ambrosio; Dan Atar; Jean-Pierre Bassand; Eivind Berge; Frank Cools; David A Fitzmaurice; Samuel Z Goldhaber; Shinya Goto; Sylvia Haas; Gloria Kayani; Yukihiro Koretsune; Lorenzo G Mantovani; Frank Misselwitz; Seil Oh; Alexander G G Turpie; Freek W A Verheugt; Ajay K Kakkar
Journal:  Heart       Date:  2016-09-19       Impact factor: 5.994

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.